Eli Lilly Beheer

Beheer criteriumcontroles 2/4

De CEO Eli Lilly is Dave Ricks, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 26.57M, bestaande uit 6.1% salaris en 93.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.067% van de aandelen van het bedrijf, ter waarde $ 475.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.2 jaar en 8.4 jaar.

Belangrijke informatie

Dave Ricks

Algemeen directeur

US$26.6m

Totale compensatie

Percentage CEO-salaris	6.1%
Dienstverband CEO	7.8yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	6.2yrs
Gemiddelde ambtstermijn bestuur	8.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dave Ricks's beloning veranderd ten opzichte van Eli Lilly's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

Compensatie versus markt: De totale vergoeding ($USD 26.57M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de CL markt ($USD 5.72M ).

Compensatie versus inkomsten: De vergoeding van Dave is het afgelopen jaar met meer dan 20% gestegen.

CEO

Dave Ricks (56 yo)

7.8yrs

Tenure

US$26,565,732

Compensatie

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% $ 475.8m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.4yrs	US$11.85m	0.021% $ 152.1m
Anat Hakim	Executive VP	4.8yrs	US$7.01m	0.0034% $ 23.9m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 16.1m
Lucas Montarce	Executive VP & CFO	less than a year	geen gegevens	0.0012% $ 8.7m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	12yrs	geen gegevens	0.00080% $ 5.7m
Diogo Rau	EVP & Chief Information and Digital Officer	3.5yrs	US$5.10m	0.0012% $ 8.7m
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.4yrs	geen gegevens	0.00088% $ 6.2m
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.9yrs	geen gegevens	0.00093% $ 6.6m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.8yrs	US$5.38m	geen gegevens
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.3yrs	geen gegevens	geen gegevens
Anne White	EVP & President of Lilly Neuroscience	6.2yrs	geen gegevens	0.0073% $ 51.5m

6.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LLY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% $ 475.8m
Gabrielle Greene-Sulzberger	Independent Director	3.8yrs	US$335.50k	geen gegevens
Sidney Taurel	Chairman Emeritus	15.8yrs	US$13.06m	geen gegevens
Jon Erik Fyrwald	Independent Director	19yrs	US$344.88k	0.000010% $ 70.8k
Ralph Alvarez	Independent Director	15.6yrs	US$336.00k	0.000080% $ 566.4k
William Kaelin	Independent Director	12.4yrs	US$349.15k	geen gegevens
Mary Hedley	Independent Director	2.5yrs	US$319.00k	0.000040% $ 283.2k
Juan Luciano	Lead Independent Director	8.8yrs	US$373.00k	geen gegevens
Katherine Baicker	Independent Director	12.9yrs	US$336.00k	geen gegevens
Jamere Jackson	Independent Director	8.1yrs	US$345.00k	geen gegevens
Karen Walker	Independent Director	5.9yrs	US$359.00k	geen gegevens
Kimberly Johnson	Independent Director	3.8yrs	US$316.00k	geen gegevens

8.4yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LLY wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).

Eli Lilly Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Recent updates

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd